Metlinka

Metformin Hydrochloride and Sitagliptin, the active ingredients in Metlinka, are a Biguanide and DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. The combination lowers hepatic glucose production, enhances insulin sensitivity, and increases incretin activity, thereby improving glycemic control in adult patients with type 2 diabetes mellitus.

GNH USA supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured antidiabetic medicines and supporting therapeutic programs through consistent supply chains and regulatory compliance.

Metlinka is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and impaired glucose regulation.

- Type 2 diabetes mellitus (monotherapy): lowers fasting plasma glucose and HbA1c when used alone. - Type 2 diabetes mellitus (combination therapy): enhances glycemic control when added to other oral antidiabetics or insulin. - Type 2 diabetes mellitus (renal impairment): provides glucose lowering with reduced risk of hypoglycaemia in patients with mild to moderate renal dysfunction.

Metlinka may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort (nausea, abdominal pain, diarrhea) - Headache - Dizziness

Serious or Rare Side Effects: - Lactic acidosis (rare but life‑threatening) - Severe hypoglycaemia, especially when combined with insulin or sulfonylureas - Acute pancreatitis or severe skin reactions (e.g., Stevens‑Johnson syndrome)

Metlinka requires careful clinical assessment before and during therapy.

- Renal function assessment: evaluate baseline eGFR and monitor periodically. - Risk of lactic acidosis: avoid in patients with severe renal or hepatic impairment. - Hypoglycaemia monitoring: caution when used with insulin or sulfonylureas. - Pregnancy and lactation: prescribe only if potential benefit outweighs risk. - Drug interaction review: assess concomitant medications for possible interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Metlinka can interact with several medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Concomitant use with phenformin or other contraindicated biguanides: risk of lactic acidosis. - IV iodinated contrast in patients with reduced renal function: may precipitate renal failure. - Insulin or sulfonylureas: increased risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metformin plasma concentrations. - Diuretics (e.g., thiazides): can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels.